Retaspimycin
Unit Price:
Get Latest Price
CAS No.:
857402-23-4
Content:
0.98%
Price valid (until):
2026-08-06
Company Type:
Manufactory
Location:
United States
Qualification:
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName Retaspimycin Cat No CEI-1501 Description Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90). Product Overview Retaspimycin is a water-soluble hydroquinone hydrochloride salt inhibitor of Hsp90. Hsp90 is a member of the Hsp family. The other members of this protein family are Hsp40, Hsp70 and so on. These proteins act as molecule chaperons and participate in many cellular processes. When cells are exposed in stress, some proteins become unstable, accumulate to form aggregates and subsequently cause cell apoptosis. In this situation, Hsps will help their client proteins folding correctly, accompany them to be translocated to the correct location and thus prevent the cells from apoptosis. Hsps are required for cancer cells development. They are found to overexpress in a variety of cancer cells. Therefore, the inhibitors of Hsp are thought to be attractive therapy for cancer treatment. As an inhibitor of Hsp90, retaspimycin works through binding to the ATP-binding pocket of Hsp90 N-terminal. In both RPMI-8826 and MM1.S cells, treatment of retaspimycin resulted in degradation of the Hsp90 client proteins, for instance, c-RAF and Her2. It also caused increased levels of Hsp70.Besides that, retaspimycin is found to prevent RPMI-8826 cells from secreting the immunoglobulin light chain. In breast cancer cells which are resistant to trastuzumab, treatment of retaspimycin potently caused Her2 degradation and resulted in tumor growth suppression and cell apoptosis. Retaspimycin is often used as combination therapy with other drugs in cancer treatment. In mice bearing GIST-882 (gastrointestinal stromal tumor) xenografts, the administration of retaspimycin associated with imatinib showed a significant effect with a 66% tumor regression. In mice bearing GIST-PSW xenografts, both the combination treatment of retaspimycin and imatinib or sunitinib showed effective antitumor activities in reducing tumor burden. When used alone, retaspimycin reduced tumor volumes by 84% and 69% in GIST-PSW and GIST-882 mice models, respectively. Moreover, retaspimycin is found to decrease the mitotic activity in these two models. However, the antimitotic effects of retaspimycin were less significant than of imatinib or sunitinib or the combination treatment. CAS No 857402-23-4 Molecular Weight 587.7 Purity 0.98 Storage Store at -20°C Synonyms IPI-504; IPI504; IPI 504,Retaspimycin Targets HSP90 Molecular Formula C31H45N3O8 Chemical Name [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6,20,22-trihydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16-oxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(22),8,12,14,18,20-hexaen-10-yl] carbamate Solubility Soluble in DMSO Shipping Conditions Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request category Specialty Chemicals(c26) cas_num 857402-23-4 Basic Info-
Product Name:
Retaspimycin
Other Name:Geldanamycin,18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propen-1-ylamino)-;Geldanamycin,18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-;18,21-Didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propen-1-ylamino)geldanamycin;17 AAGH2;Retaspimycin
CAS No.:857402-23-4
Molecular Formula:C31H45N3O8
InChIKeys:InChIKey=OAKGNIRUXAZDQF-TXHRRWQRSA-N
Molecular Weight:587.7
Exact Mass:587.70
UNII:BZF2ZM0I5Z
NCI Thesaurus Code:C80378
Categories:
Characteristics -
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product